Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study

被引:25
|
作者
Ruiz, JC
Diekmann, F
Campistol, JM
Sanchez-Fructuoso, A
Rivera, C
Oliver, J
Fernandez-Fresnedo, G
Arias, M
机构
[1] Univ Cantabria, Mar Valdecilla Hosp, E-39005 Santander, Spain
[2] Hosp Clin Barcelona, Renal Transplant Unit, Barcelona, Spain
[3] Univ Clin Hosp, Dept Nephrol, Madrid, Spain
[4] Juan Canalejo Hosp, Dept Nephrol, Coruna, Spain
[5] Univ Cantabria, Dept Nephrol, E-39005 Santander, Spain
关键词
D O I
10.1016/j.transproceed.2005.09.127
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) has become an option in patients with chronic allograft nephropathy or other conditions. However, in some cases an increase of proteinuria has been reported after such therapeutic intervention. The aim of this study was to characterize the clinical course of this so far unexplained proteinuria after conversion. We performed a retrospective analysis evaluating 94 renal transplant patients from various Spanish centers. Proteinuria (629 determinations) and clinical developments were analyzed between 6 months before and 6 months after conversion. Patients were divided into three groups according to mean proteinuria before conversion (group A: < 300 mg/d; group 13: 300 to 2000 mg/d; and group C: > 2 g/d). The mean proteinuria level was 1.69 g/24 h (n = 312 determinations) before and 2.36 g/24 h after conversion (n = 317 determinations; P=.006), which corresponds to an overall increase of 25% (1.55 to 1.69 g/24 h considering only determinations of 1 month before and 1 month after conversion; P = NS). We could not detect any clear correlation between proteinuria and serum creatinine nor between changes of proteinuria and changes of serum creatinine. A variance analysis for repeated measures showed an increase in proteinuria compared to the preconversion values (P =.003), and when the three groups of preconversion proteinuria were evaluated separately it could be observed that this change in the evolution of proteinuria was almost completely dependent of an increase in the group C (preconversion proteinuria greater than 2 g/d; P =.03), whereas in the other two groups changes were almost irrelevant. Finally, the switch to SRL in renal transplant recipients is followed by an increase in the level of proteinuria predominantly dependent of an increase in patients with high levels of preconversion proteinuria, whereas it seems to be irrelevant in patients without or with light or moderate proteinuria. These results suggest that this might not be a direct effect of SRL.
引用
收藏
页码:3833 / 3835
页数:3
相关论文
共 50 条
  • [41] Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients
    Diekmann, F
    Fritsche, L
    Neumayer, HH
    Budde, K
    KIDNEY & BLOOD PRESSURE RESEARCH, 2004, 27 (03): : 186 - 190
  • [42] Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus
    Bumbea, V
    Kamar, N
    Ribes, D
    Esposito, L
    Modesto, A
    Guitard, J
    Nasou, G
    Durand, D
    Rostaing, L
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (11) : 2517 - 2523
  • [43] Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria
    Saurina, A
    Campistol, JM
    Piera, C
    Diekmann, F
    Campos, B
    Campos, N
    de las Cuevas, X
    Oppenheimer, F
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (02) : 488 - 493
  • [44] Proteinuria following switch from calcineurin inhibitors to sirolimus:: A retrospective study.
    Letavernier, E
    Péraldi, MN
    Kreis, H
    Legendre, C
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 161 - 161
  • [45] Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients
    Tsai, Kai-Fan
    Li, Lung-Chih
    Hsu, Chien-Ning
    Lin, Chih-Che
    Lin, Yu-Hung
    Cheng, Yu-Fan
    Wang, Chih-Chi
    Chen, Chao-Long
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (03): : 326 - 334
  • [46] Sirolimus (SRL) and its effects after 12 month therapy on patients with calzineurin (CNI) induced renal dysfunction
    Hariri, K.
    Roedler, S.
    Dunkler, D.
    Szent-Ivanyi, E.
    Aliabadi, A.
    Grimm, M.
    Wollner, E.
    Zuckermann, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (02): : S151 - S152
  • [47] Conversion from calcineurin inhibitors to sirolimus in renal transplantation; One center experience
    Ozkan, Oktay
    Yazici, Halil
    Caliskan, Yasar
    Ozturk, Savas
    Turkmen, Aydin
    Sever, Mehmet Sukru
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 266 - 266
  • [48] INITIATION OF EVEROLIMUS WITH CALCINEURIN INHIBITOR (CNI) REDUCTION IN THORACIC TRANSPLANT PATIENTS WITH IMPAIRED RENAL FUNCTION: A MULTICENTER, RANDOMIZED STUDY
    Gullestad, Lars
    Iversen, Martin
    Eiskjaer, Hans
    Riise, Gerdt C.
    Solbu, Dag
    Bergh, Claes-Hakan
    TRANSPLANT INTERNATIONAL, 2009, 22 : 53 - 54
  • [49] An openpilot study on the safety of a conversion from calcineurin inhibitors to sirolimus in patients with moderately impaired function of renal transplants.
    Fischereder, M
    Graeb, C
    Kammerl, MC
    Zuelke, C
    Jauch, KW
    Kramer, BK
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 770A - 770A
  • [50] A Randomized, Open-Label Study To Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor (CNI) to Sirolimus Versus Continued Use of a CNI in Cardiac Transplant Recipients with Mild to Moderate Renal Insufficiency
    Zuckermann, A.
    Keogh, A.
    Crespo-Leiro, M. G.
    Mancini, D.
    Gonzalez-Vilchez, F.
    Almenar, L.
    Brozena, S.
    Eisen, H.
    Tai, S. See
    Kashwaha, S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (02): : S85 - S85